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Head and neck cancer is a disease which is usually treated with
radiotherapy, surgery alone or a combination of surgery and pre- or
post-operative radiotherapy. Treatment decisions are usually based
not only on results from previous trials, patient parameters (perfor-
mance status, age, weight loss, other co-existing diseases) and
clinicopathological factors (site, TNM status, grade of differentia-
tion) but also on local treatment traditions. The latter will favour
either radical radiotherapy, surgery, or a combined modality
approach. The advantages of radiotherapy over surgery in the
management of the disease is in the possibility of organ preserva-
tion and maintenance of important functions (e.g. speaking, swal-
lowing). The advantages of surgery are short overall treatment
times and less radiotherapy-specific morbidity (e.g. dry mouth,
taste alteration and radionecrosis). The potential value of finding
biological predictive factors is in being able to offer an individual-
ized approach to treatment to select the most appropriate type of
therapy. In theory this should lead to not only increases in local
control but also reductions in treatment-specific morbidity.
Regarding biological predictive factors for radiotherapy
response, tumour proliferation is probably the most widely studied
parameter, in particular the potential doubling time (Tpot) of a
tumour (Bourhis et al, 1993; Begg et al, 1995; Zackrisson et al,
1997). However, a recent meta-analysis of 210 aneuploid tumours
treated with conventional radiotherapy showed that labelling index
(LI) but not Tpot was a significant predictor of local control
(Begg, 1997). Nevertheless, there are statistical and methodo-
logical questions regarding the appropriateness of pooling multi-
centre data and using Tpot as a continuous variable (Coucke et al,
1998). There is, therefore, still interest in measuring proliferation
in head and neck cancers.
Another potential biological prognostic parameter for radio-
therapy response is tumour radiosensitivity, usually measured as
surviving fraction at 2 Gy (SF2) (West, 1995). There is good
evidence that in-vitro clonogenic assays reflect the radiorespon-
siveness of tumour in vivo (reviewed in West, 1995). In particular,
in cervix tumours SF2 has been shown to be an independent
prognostic factor for radiotherapy response (West et al, 1997). The
results from studies on head and neck cancer, however, have been
disappointing. SF2 measured using the CAM (cell adhesive
matrix) assay on tumour specimens from patients treated by radio-
therapy and surgery showed a trend for patients with in vitro radio-
resistant versus -sensitive tumours to have a worse outcome but
the difference was not significant (Brock et al, 1990). Using the
same assay, a study on patients treated predominantly by radio-
therapy alone showed that tumour radiosensitivity was signifi-
cantly associated with treatment outcome (Girinsky et al, 1994)
but in a recent update of the data the significance was lost
(Eschwege et al, 1997). Thus, it is yet to be established whether
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Summary A study was made of the relationship between measurements of radiosensitivity versus proliferation and p53 status in head and
neck cancers. Inherent tumour radiosensitivity was assessed as surviving fraction at 2 Gy (SF2) using a clonogenic soft agar assay (n = 77).
The results were compared to data on proliferation obtained by both flow cytometry (labelling index (LI), the potential doubling time (Tpot)
n = 55) and immunohistochemistry (Ki-67 and PCNA; n = 68), together with immunohistochemical p53 expression (n = 68). There were no
overall significant differences in the median values of the various parameters analysed for the different sites within the head and neck region,
disease stages, grades of tumour differentiation or nodal states. A subgroup analysis showed that oropharyngeal (n = 22) versus oral cavity
(n = 35) tumours were more radiosensitive (P = 0.056) and had a higher Ki-67 index (P = 0.001). Node-positive tumours had higher LI
(P = 0.021) and a trend towards lower Tpot (P = 0.067) values than node-negative ones. No correlations were seen between SF2 and any of
the parameters studied. The long-standing dogma of an increased radiosensitivity of rapidly proliferating cells in contrast to slowly
proliferating cells was not confirmed. The study shows that parallel measurements of different biological markers can be obtained for a large
number of patients with head and neck cancers. The independence of the various parameters studied suggests that there may be potential
for their combined use as prognostic factors for the outcome of radiotherapy.
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radiosensitivity measurements obtained using a clonogenic assay
are prognostic for radiotherapy outcome in head and neck cancers.
Although we have carried out a large study measuring tumour
radiosensitivity using a soft agar assay (Björk-Eriksson et al,
1998), analysis with respect to treatment outcome awaits adequate
patient follow-up.
The TP53 gene is important in the pathogenesis of cancer and
mutations in it are the most common found in human cancers. The
TP53 gene also has a clear role to play in regulating cell prolifera-
tion and radiosensitivity and as a checkpoint protein trans-
activating other genes (Yin et al, 1992; Bristow et al, 1996).
With the possible exceptions of laryngeal- and oropharyngeal
carcinomas (Sauter et al, 1992; Bradford et al, 1995; Narayana
et al, 1998), most studies using immunohistochemistry have not
shown any correlation between p53 overexpression and local
control or survival in head and neck cancers (Field et al, 1993;
Raybaud-Diogene et al, 1997). Therefore, it is of interest to study
the relationship between p53 overexpression versus inherent
tumour radiosensitivity and proliferation.
There is little information on the relationship between radio-
sensitivity and proliferation in the same patient, and between SF2
and p53 expression in primary tumours. Therefore, the aims of this
study were to examine the relationship between SF2, various
proliferation parameters (Ki-67, PCNA, LI, Tpot) and p53 expres-
sion for a large number of patients with head and neck cancers.
MATERIALS AND METHODS
Specimens
All tumour material was obtained following informed consent.
Biopsy or surgical specimens were taken from patients with previ-
ously histopathologically confirmed and untreated primary squa-
mous cell- or undifferentiated carcinoma of the head and neck
region. Samples were collected for radiosensitivity testing, flow-
cytometric analysis and routine histopathology, including later
immunohistochemical staining. The specimens were divided and
portions were placed in transport medium (Björk-Eriksson et al,
1998), 70% ethanol and 4% formaldehyde for the various analyses
to be carried out later. All the material was from primary lesions
and no selection criteria were used regarding tumour site of origin
within the head and neck region or TNM-stage (Spiessl et al,
1990). The specimens were collected from the Department of
Otorhinolaryngology Head and Neck Surgery, Sahlgrenska
University Hospital in Gothenburg, Sweden.
Radiosensitivity
Tumour radiosensitivity was measured on primary biopsies as the
surviving fraction following an acute exposure of 2 Gy in vitro
(SF2) using a soft agar clonogenic assay. The materials and
methods used have been described in detail elsewhere together
with a description of the immunohistochemical characterization of
the malignant epithelial origin of colonies (Björk-Eriksson et al,
1998).
Immunohistochemistry
Formalin-fixed and paraffin-embedded sections, 5-mm thick, were
stained using the DAKO Techmate500–1000™ automated system.
The following antigens (all DAKO™) and dilutions were used:
1/500 anti-human p53 mouse monoclonal antibody (clone DO-7),
1/100 anti-Ki-67 rabbit polycolonal antibody (reactivity similar to
MIB-1), and 1/50 anti-PCNA mouse monoclonal antibody (clone
PC-10). A microwave antigen retrieval step was used for p53 and
Ki-67 only. Both primary and secondary antibodies were incu-
bated for 25 min at room temperature. For Ki-67 and PCNA,
normal human pharyngeal tonsil was used as a positive control,
and for p53, a known positive human rectal carcinoma served as
the positive control. The presence of carcinoma and the number of
immunohistochemically stained cells were scored under a light
microscope by two independent observers using a 100 squared
grid and a magnification of ´400. All viable nucleated tumour
cells at the 121 crossings of the grid were counted and scored as
positive or negative. When there was sufficient tumour material,
this procedure was repeated five times for each observer to give a
total of up to 1210 cells scored. The percentage of positive nuclei
was used as a measure of antigen expression.
Flow cytometry
Administration of bromodeoxyuridine (BrdU) was carried out
following approval from the Ethical Committee of the University
of Gothenburg, Sweden. A short time intravenous (i.v.) infusion
of 250 mg BrdU dissolved in 100 ml natural saline was given
approximately 6 h before biopsy. Nuclei extraction, DNA staining,
analysis on the FACS scan flow cytometer (Becton-Dickson) and
Table 1 Description of clinical parameters
Parameter Group n
Sex Male 59
Female 18
Site Oral 35
Oropharynx 22
Nasopharynx 8
Hypopharynx 3
Larynx 7
Sinonasal 2
Stage II 8
III 14
IV 54
Nodes Negative (Na = 0) 44
Positive (N = 1–3) 32
Histology SCC 77
Poor 22
Moderate 38
Well 7
Undifferentiated 3
aRefers to TNM classification according to UICC. SCC, squamous cell
carcinoma.
Table 2 Summary of data
Variable n Mean ± ± 1 s.d. Median Range
Age (years) 77 63 ± 14 63 19–94
SF2 77 0.46 ± 0.21 0.40 0.10–1.00
p53 (%) 68 18 ± 27 2 0–85
Ki-67 (%) 67 21 ± 14 18 2–60
PCNA (%) 68 21 ± 23 14 0–92
LI (%) 55 8 ± 5 7 1–24
Tpot (h) 50 128 ± 117 107 11–6601402 T Björk-Eriksson et al
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the calculations of LI as well as Tpot were performed as described
previously (Lydén et al, 1995).
Statistical analysis
Correlations between variables were determined using Spearman’s
rank correlation. Subset analyses were carried out with groups of
more than 30 patients, which had 80% power to detect a significant
correlation. The Mann–Whitney U-test and Kruskal–Wallis one-
way analysis of variance were used to test for the level of signifi-
cance between independent variables. A significance level of 0.05
was used throughout.
RESULTS
SF2 values were obtained for 77 patients with head and neck
malignancies. Table 1 summarizes the distribution of the patients
according to sex, site, stage, nodal status and histology. Staging
information was not available for one patient and seven tumours
were classified as squamous cell carcinoma only with no further
indication of the degree of differentiation. Table 2 summarizes the
data for tumour radiosensitivity (SF2), patient age and the various
immunohistochemical (p53, Ki-67, PCNA) and flow cytometry
(LI, Tpot) parameters. Immunohistochemical scoring of the three
antibodies studied were well-correlated for the two independent
observers: p53 (r = 0.90, P < 0.001), Ki-67 (r = 0.81, P < 0.001)
and PCNA (r = 0.88, P < 0.001). In contrast, there was consider-
able inter-tumour variability in immunohistochemical expression
with coefficients of variation of 150%, 67% and 151% for p53,
Ki-67 and PCNA respectively.
Before correlations between variables were obtained, an analysis
was made of the distribution of values within the different sites of
the head and neck region, disease stages, grades of tumour differen-
tiation and tumour nodal status. Using the Kruskal–Wallis non-
parametric test, there were no significant differences in the median
values of the various parameters for the different sites within the
head and neck region (Table 3). A subgroup analysis was made of
the two most frequently-presenting sites. Oropharyngeal tumours
were more radiosensitive (P = 0.056) and had a higher Ki-67 index
(P < 0.001) than carcinomas of the oral cavity. There were no
significant differences in the median values of the various parame-
ters for the different disease stages (Table 4; P > 0.14) and grades of
Table 3 Distribution within the different tumour sites of the head and neck
Site SF2 p53 Ki-67 PCNA LI Tpot
(%) (%) (%) (%) (h)
Oral cavity 0.51 ± 0.23 19 ± 27 15 ± 12 21 ± 24 7 ± 5 121 ± 82
n =3 5 3 1 3 1 3 1 2 4 2 0
Oropharynx 0.38 ± 0.19 16 ± 27 27 ± 14 25 ± 21 9 ± 5 124 ± 116
n =2 2 2 1 2 1 2 1 1 4 1 3
Nasopharynx 0.45 ± 0.18 17 ± 25 21 ± 14 5 ± 77   ± 4 173 ± 218
n =8 5 5 5 7 7
Hypopharynx 0.28 ± 0.06 18 ± 30 35 ± 10 37 ± 41 16 ± 7 32 ± 24
n =3 3 3 3 3 3
Larynx 0.45 ± 0.12 8 ± 13 23 ± 11 16 ± 12 8 ± 5 154 ± 105
n =7 6 5 6 5 5
Sinonasal 0.68 ± 0.37 77 ± 1 26 ± 34 4 ± 36   ± 2 144 ± 60
n =2 2 2 2 2 2
All values represent mean ± one standard deviation.
Table 4 Subset analysis according to stage (II, III and IV) and tumour
differentiation (Diff) (Poor, Mod and Well)
Stage/ SF2 p53 Ki-67 PCNA LI Tpot
Diff. (%) (%) (%) (%) (h)
II 0.59 ± 0.23 12 ± 18 13 ± 8 12 ± 13 5 ± 4 120 ± 13
n =8 7 7 7 3 2
III 0.40 ± 0.15 27 ± 33 23 ± 16 13 ± 19 8 ± 4 109 ± 76
n =1 4 1 3 1 3 1 3 1 0 7
IV 0.44 ± 0.20 17 ± 27 22 ± 14 24 ± 24 8 ± 5 133 ± 127
n =5 4 4 7 4 6 4 7 4 1 4 0
Poor 0.46 ± 0.20 15 ± 26 25 ± 17 21 ± 20 95 121 ± 114
n =2 2 2 0 2 0 2 0 1 6 1 5
Mod 0.44 ± 0.22 26 ± 31 21 ± 14 21 ± 21 8 ± 5 119 ± 83
n =3 8 3 4 3 4 3 4 2 5 2 1
Well 0.44 ± 0.18 5 ± 8 17 ± 11 33 ± 38 12 ± 9 73 ± 52
n =7 7 7 7 4 4
All values represent mean ± one standard deviation. Stage II, III and IV refers
to the TNM classification according to UICC (Spiessl et al, 1990). Tumour
differentiation: Poor = poorly differentiated squamous cell carcinoma; Mod =
moderately differentiated squamous cell carcinoma; Well = well-differentiated
squamous cell carcinoma.
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Figure 1 The lack of relationship between tumour radiosensitivity (SF2) and
the percentage of cells stained p53 positive for 68 head and neck tumours
(r = 0.17, P = 0.17)
Figure 2 The lack of relationship between tumour radiosensitivity (SF2) and
proliferation (Tpot) for 50 cancers of the head and neck (r = 0.07, P = 0.64)Proliferation and radiosensitivity in head and neck cancers 1403
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tumour differentiation (Table 5; P > 0.44). Node-positive tumours
had higher values for LI (P = 0.021) and tended to have lower
values for Tpot (P = 0.067) than node-negative cancers.
The relationships between variables were investigated using
Spearman’s rank correlation. No significant correlations were seen
between SF2 and Ki-67 index (r = –0.19, P = 0.13), PCNA index
(r = –0.10, P = 0.40), or LI (r = –0.10, P = 0.46). The Figures illus-
trate the lack of relationship between SF2 versus p53 expression
(Figure 1) and Tpot (Figure 2). The analyses were repeated for the
largest clinical subgroups. No significant correlations were also
seen when the data were reanalysed for oral cavity (P > 0.061),
stage IV disease (P > 0.49) or moderately differentiated tumours
(P > 0.28) only.
Significant correlations were seen between some of the other
parameters. As expected, LI and Tpot were highly significantly
correlated (n = 50, P < 0.001). A significant correlation was also
seen between the expression of the two proliferative markers, Ki-
67 and PCNA (n = 67, P = 0.036). There were no significant rela-
tionships between the level of p53 expression and any of the
proliferation parameters.
DISCUSSION
The individualization of radiotherapy using biological predictive
tests alongside the traditional patient and clinicopathological para-
meters could lead to not only increased local control, but also less
morbidity. The prognostic factors of most interest are those which
are known to affect radiotherapy outcome, namely tumour prolif-
eration, radiosensitivity and oxygenation, and the intrinsic
radiosensitivity of normal cells. There have now been numerous
studies that have examined the potential of all these parameters as
prognostic factors for radiotherapy outcome (Begg, 1997). It may
be, however, that the greater discrimination of radiotherapy
outcome groups will be via multiple biological tests. For example,
large differences in survival and local control probabilities have
been shown by combining two biological parameters (Levine et al,
1995; Raybaud-Diogene et al, 1997; West et al, 1998). It is of
interest, therefore, to examine the relationship between potential
prognostic factors in order to show both their independence and
the feasibility of carrying out multiple measurements. It is
surprising then that there are little data where measurements have
been made of SF2 and Tpot on primary tumours form the same
individual. A paper, where Tpot and SF2 had been obtained on
only nine patients, highlighted some of the problems in carrying
out parallel measurements such as inadequate sample size and
patient refusal (Eschwege et al, 1997).
In the work described here, tumour Tpot measurements were
made on 50 out of 77 (65%) patients for whom SF2 data were
collected. Reasons for failure to obtain Tpot data were predomi-
nately related to patient refusal and age. Nevertheless, we have
clearly demonstrated that it is feasible to make multiple biological
measurements. In addition, our work has shown that there is no
relationship between the intrinsic radiosensitivity of a tumour and
its rate of proliferation, whether measured by flow cytometry or
the simpler immunohistochemical methods. This finding is
supported by work carried out on cells in culture which has shown
that there is no relationship between intrinsic radiosensitivity and
the in vitro proliferation rate measured either as cell doubling time
(Pekkola-Heino et al, 1994) or as LI and Tpot (Warenius et al,
1994). The lack of relationship between SF2 and Tpot/LI is
encouraging for the future parallel assessment of radiosensitivity
and proliferation. It has been suggested that it may be necessary to
correct for differences in tumour radiosensitivity before tests
based on other radiobiological parameters may have clinical
significance (Tucker and Thames, 1989). It will, therefore, be of
interest in the future to examine the prognostic significance of LI
(and the other proliferation measures) after allowing for differ-
ences in tumour radiosensitivity.
Over the past decade there has been considerable interest in
measuring the tumour suppressor and regulatory gene p53
product. In cancers of the head and neck, overexpression of p53
has been studied in relation to local control (Wilson et al, 1995;
Narayana et al, 1998), survival (Sauter et al, 1992; Field et al,
1993; Nylander et al, 1995) and lately organ preservation
(Bradford et al, 1995). In general, p53 expression using immuno-
histochemistry is not a significant prognostic factor for radio-
therapy outcome and the use of functional assay has been
suggested (Bristow et al, 1996). However, there is still interest in
studying the relationship between tumour p53 expression and
radiosensitivity as the findings have been equivocal. In a series of
24 head and neck cancer cell lines, Brachman et al (1993) found
no relationship between p53 mutations and SF2. However, in 16
oral cavity carcinoma cell lines, the 11 lines that had a mutated p53
gene were significantly more radiosensitive than those with wild-
type p53 (Pekkola-Heino et al, 1996). Studies on other tumour
types have yielded different results with some showing a signifi-
cant association (Siles et al, 1996) and others not (Zaffaroni et al,
1995). In our work we have shown no relationship between SF2
and p53 expression, measured using immunohistochemistry in
mixed cancers of the head and neck or in a subsite analysis of 31
oral cavity tumours (r = 0.24, P = 0.20). One of the principal func-
tions of p53 is the induction of cell cycle arrest. As loss of wild-
type expression is associated with cellular growth, a relationship
might be expected between p53 expression and proliferation. This
was not found either in our study or the work of others on head and
neck cancer (Wilson et al, 1995). There are several possible
reasons. First, it may be a methodological problem relating to the
use of immunohistochemistry rather than mutational analysis.
Immunohistochemistry using the DO7 antibody has been reported
to have concordance with mutational analysis in 71% of head and
neck cancers, while 14% were DO7-positive with no detected
mutations and 15% had TP53 mutations not detected by DO7
(Calzolari et al, 1997). Second, a lack of correlation between p53
expression and proliferation may relate to the variety of different
effects mediated via p53. Third, it may be important to investigate
a single tumour site within the head and neck. In support of the
latter, Bourhis et al (1994) showed a significant correlation
between p53 overexpression and short Tpot in 49 oropharyngeal
cancers. Regarding the relationship between p53 and proliferation,
more information would be gained by carrying out mutational
analysis of TP53 and by concentrating on a single tumour type.
Although this is a limitation of the present study, our primary
objective was to obtain radiosensitivity measurements on a large
number of tumours, and correlate the radiosensitivity data with
other biological parameters.
In summary, this work has highlighted the feasibility of carrying
out multiple measurements of radiobiological parameters on
patients with cancers of the head and neck. No correlations were
seen between SF2 and measures of proliferation and p53 expres-
sion. All the patients included in this study were treated with
radiotherapy, but follow-up times were too short to allow correla-
tions with clinical outcome. However, in the future we will1404 T Björk-Eriksson et al
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examine the relationships between the various factors studied and
radiation response in vivo.
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